| Literature DB >> 25381665 |
Yalin Yang1, Jie Xiong2, Zhigang Zhou1, Fengmin Huo3, Wei Miao4, Chao Ran3, Yuchun Liu3, Jinyong Zhang4, Jinmei Feng4, Meng Wang5, Min Wang6, Lei Wang6, Bin Yao1.
Abstract
Members of Myxozoa, a parasitic metazoan taxon, have considerable detrimental effects on fish hosts and also have been associated with human food-borne illness. Little is known about their biology and metabolism. Analysis of the genome of Thelohanellus kitauei and comparative analysis with genomes of its two free-living cnidarian relatives revealed that T. kitauei has adapted to parasitism, as indicated by the streamlined metabolic repertoire and the tendency toward anabolism rather than catabolism. Thelohanellus kitauei mainly secretes proteases and protease inhibitors for nutrient digestion (parasite invasion), and depends on endocytosis (mainly low-density lipoprotein receptors-mediated type) and secondary carriers for nutrient absorption. Absence of both classic and complementary anaerobic pathways and gluconeogenesis, the lack of de novo synthesis and reduced activity in hydrolysis of fatty acids, amino acids, and nucleotides indicated that T. kitauei in this vertebrate host-parasite system has adapted to inhabit a physiological environment extremely rich in both oxygen and nutrients (especially glucose), which is consistent with its preferred parasitic site, that is, the host gut submucosa. Taking advantage of the genomic and transcriptomic information, 23 potential nutrition-related T. kitauei-specific chemotherapeutic targets were identified. This first genome sequence of a myxozoan will facilitate development of potential therapeutics for efficient control of myxozoan parasites and ultimately prevent myxozoan-induced fish-borne illnesses in humans.Entities:
Keywords: Myxozoa; food-borne illness; genome and transcriptome; nutrient deprivation
Mesh:
Substances:
Year: 2014 PMID: 25381665 PMCID: PMC4986447 DOI: 10.1093/gbe/evu247
Source DB: PubMed Journal: Genome Biol Evol ISSN: 1759-6653 Impact factor: 3.416
Summary of Genomic Features of Thelohanellus kitauei and Two Free-Living Cnidarians
| Genome features | Parasitic | Free-Living | |
|---|---|---|---|
| Total genome size (Mb) | 150.7 | 852.2 | 356.6 |
| Total coding size (Mb) | 20 | 21.5 | 30.5 |
| Total coding ratio (%) | 13.3 | 2.5 | 8.6 |
| Gene number | 16,638 | 17,918 | 26,676 |
| Average gene length (kb) | 1,210 | 14,568 | 5,869 |
| Gene density (genes per Mb) | 110 | 21 | 75 |
| Average coding sequence size (kb) | 717 | 1,267 | 1,223 |
| Average exon number | 3 | 6 | 5 |
| Average exon size (bp) | 235 | 218 | 208 |
| Average intron size (bp) | 240 | 2,653 | 1,122 |
| Total GC content (%) | 37.5 | 27.8 | 40.6 |
| GC content in coding region (%) | 39.0 | 33.5 | 46.5 |
FOverall function catalogs of T. kitauei gene annotation. Function catalogs described in this study are highlighted in red.
FComparison of proteases in T. kitauei and other organisms. Values above column are the percentage of the proteases within the total proteome of that species.
FAn overview of nutrient digestion, absorption and metabolism in T. kitauei, as deduced from genome sequence analysis. The color-coding in the secretory digestive enzymes of T. kitauei: red, proteases; blue, proline iminopeptides; orange, carbohydrate-binding module family proteins and glycoside hydrolases; yellow, lipase. Transporters are grouped by substrate specificity: red, amino acids/peptides/proteins; orange, sugars and derivative; yellow, lipids; green, nucleotides/nucleosides; purple, vitamins and cofactors; pink, dicarboxylates and others organic; blue, cations and anions; black, drugs/toxic compounds; gray, unknown substrates; numbers indicated the number of predicted transporters of each type. The color-coding in metabolism of T. kitauei indicates: blue, enzymes or pathways present in all three species, T. kitauei, H. magnipapillata, and N. vectensis; green with a cross, enzymes or pathways present in at least one of the two free-living cnidarians but absent in T. kitauei; gray with a cross, enzymes or pathways absent in all three species; red, enzymes or pathways present only in T. kitauei; orange, putative functions. Amino acids that can be de novo synthesized and catabolized (a) or partially synthesized and catabolized (b) or only catabolized (c) by the two free-living cnidarians. Unbroken arrows indicate direct steps in a pathway, and broken arrows indicate multiple steps in a pathway not shown. Amino acids are indicated in the three letter code. AAAP, amino acid/auxin permease; APC, amino acid-polyamine-organocation family; ArsAB, arsenite-antimonite efflux family; ABC, ATP-binding cassette superfamily; AT-1, autotransporter-1; AEC, auxin efflux carrier; DcuC, C4-dicarboxylate uptake C; CaCA, Ca2+:cation antiporter family; Hsp70, cation channel-forming heat shock protein-70 family; CDF, cation diffusion facilitator; ClC, chloride carrier/channel family; DASS, divalent anion: Na+ symporter; DMT, drug/metabolite transporter; ENT, equilibrative nucleoside transporter; GBP, general bacterial porin; Sec, general secretory pathway family; GPH, glycoside-pentoside-hexuronide: cation symporter; F-ATPase, H+- or Na+-translocating F-type, V-type and A-type ATPase; PiT, inorganic phosphate transporter; MFS, major facilitator superfamily; MC, mitochondrial carrier; CPA1, monovalent cation: proton antiporter-1; OAT, organo anion transporter; OMF, outer membrane factor; FUP, outer membrane fimbrial usher porin family; OMR, outer membrane receptor; FAT, proposed fatty acid transporter; POT, proton-dependent oligopeptide transporter; COX, proton-translocating cytochrome oxidase; NDH, proton-translocating NADH dehydrogenase; QCR, proton-translocating quinol: cytochrome c reductase; Glc, PTS glucose-glucoside; P-ATPase, P-type ATPase; RND, resistance-nodulation-cell division; SulP, sulfate permease; TRP-CC, transient receptor potential Ca2+ channel; VIC, voltage-gated ion channel; ZIP, zinc (Zn2+)-iron (Fe2+) permease; PEP, phosphoenolpyruvic acid; NADH, nicotinamide adenine dinucleotide; Q, quinine; AOX, alternative oxidase; CI to CIV, complex I to complex IV; C, cytochrome c; ANT, adenine nucleotide translocator; FAD, flavin adenine dinucleotide; FADH2, reduced FAD; ADP, adenosine diphosphate; FOLR, folate receptor; GPCR, G protein-coupled receptors; LDLR, low-density lipoprotein receptor; Hsc70, heat shock 70 kDa protein 1/8; ATPev, V-type H+-transporting ATPase; LIMP, lysosomal integral membrane protein; NPC, niemann-pick C protein; LYPLA3, lysophospholipase III; LAMAN, lysosomal alpha-mannosidase; F-actin, actin beta/gamma 1; TCA, tricarboxylic acid.
FComparison of transporters of T. kitauei and other organisms. Values above column are the percentage of the transporters within the total proteome of that species.
FNumber of metabolic reactions (A) and number of metabolic genes (B) in comparison between T. kitauei and two free-living cnidarias.
Promising Thelohanellus kitauei-Specific Drug Targets (23) Relating to Nutrient Process
| Gene ID | Predicted Protein | Function Category | Previous Indications As Drug Target |
|---|---|---|---|
| evm.model.scaffold04826.5 | Peptidyl-prolylcis-trans isomerase FKBP4 | Transport | Antiparasitic targets ( |
| evm.model.scaffold05481.72 | Vesicular glutamate transporter 3 | ||
| evm.model.scaffold02466.3 | |||
| evm.model.scaffold00373.8 | Integrin beta 2 | Endocytosis | Antiinflammatory target ( |
| evm.model.scaffold04701.1 | Heterogeneous nuclear ribonucleoprotein K | Anticancer target ( | |
| evm.model.scaffold01071.3 | Sortilin | Target for Alzheimer's disease ( | |
| evm.model.scaffold01071.5 | |||
| evm.model.scaffold05633.24 | Low-density lipoprotein-related protein 2 | Target for Alzheimer's disease ( | |
| evm.model.scaffold04423.69 | |||
| evm.model.scaffold01248.6 | Arachidonate 5-lipoxygenase | Lipid metabolism | Anticancer target ( |
| evm.model.scaffold04176.12 | 17 beta-estradiol 17-dehydrogenase | Anticancer target ( | |
| evm.model.scaffold00813.1 | Diacylglycerol kinase (ATP dependent) | Targets for cancer ( | |
| evm.model.scaffold04610.1 | Phospholipase D3 | Target in disease settings ( | |
| evm.model.scaffold05340.25 | Oligosaccharyltransferase complex subunit beta | Glycan biosynthesis | Target for |
| evm.model.scaffold00661.36 | 2,3-bisphosphoglycerate-independent phosphoglyceratemutase | Carbohydrate metabolism | Anticancer ( |
| evm.model.scaffold03068.51 | Inositol-tetrakisphosphate 1-kinase | Antimalarial target ( | |
| evm.model.scaffold01538.6 | Inositol-1,4,5-trisphosphate 5-phosphatase | Antimalarial target ( | |
| evm.model.scaffold01687.1 | Ribokinase | Antibacterial target ( | |
| evm.model.scaffold04623.113 | Pyrazinamidase/nicotinamidase PNCA | Cofactor metabolism | Target for |
| evm.model.scaffold02481.37 | |||
| evm.model.scaffold03983.31 | Thiamine pyrophosphokinase | Antimalarial target ( | |
| evm.model.scaffold04174.4 | Ectonucleoside triphosphate diphosphohydrolase 4 | Nucleotide metabolism | Anticancer target ( |
| evm.model.scaffold02448.28 | Glutathione S-transferase | Other amino acid metabolism | Antimesothelioma ( |